Comparison at a glance: Injection vs. Pill
Both forms of Wegovy® use the same active ingredient — semaglutide — but the day-to-day experience is quite different. Use the table below to compare the two at a glance before reading the detail underneath.
|
|
|
| Feature |
Wegovy® Injection |
Wegovy® Pill |
| Active ingredient |
Semaglutide |
Semaglutide |
| Frequency |
Once weekly |
Once daily |
| Administration |
Subcutaneous (under the skin) |
Oral tablet |
| Timing |
Any time, with or without food |
Morning only, on an empty stomach |
| Absorption requirements |
High bioavailability (direct) |
Requires a 30-minute fast after taking |
| Storage |
Refrigerated (long-term) |
Room temperature |
| Clinical weight loss |
~14.9% to 16% (average) |
~13.6% to 16.6% (average) |
Key evidence-based differences
1. Effectiveness and “bioavailability”
Both forms are highly effective, but they reach your bloodstream differently. The injection has a high bioavailability (around 89%), meaning most of the medication is absorbed directly. Because the pill must survive the harsh environment of the stomach, its bioavailability is much lower (around 1–2%).
To compensate for this, the pill contains a specialised ingredient called SNAC (salcaprozate sodium) to help the stomach absorb the semaglutide, and the dose is significantly higher than the injection.
2. Clinical outcomes
Clinical data from the STEP (injection) and OASIS (pill) trial programmes show comparable results:
- Wegovy injection: In the STEP 1 trial, participants lost an average of 14.9% of their body weight over 68 weeks.
- Wegovy pill: In the OASIS 4 trial, participants taking a 25 mg daily dose achieved an average weight loss of 16.6% over 64 weeks.
3. The “30-minute rule” for the pill
One of the most significant lifestyle differences is the morning routine. To ensure the pill works correctly, it must be taken:
- First thing in the morning on an empty stomach.
- With no more than 120 ml (half a glass) of plain water.
- At least 30 minutes before eating, drinking anything else, or taking other oral medications.
Skipping this window can significantly reduce how much medicine your body absorbs.
4. Side effects
Because both use semaglutide, the side effect profiles are very similar. The most common issues are gastrointestinal, such as nausea, diarrhoea, and constipation. Some patients find the injection causes mild redness at the site of the shot, while some evidence suggests the pill may occasionally cause more direct stomach irritation (heartburn or gas) due to oral ingestion.
Which option might suit you?
The injection may be better if:
- You prefer a “set and forget” approach once a week.
- You find it difficult to wait 30 minutes for coffee or breakfast in the morning.
- You travel frequently and can manage the refrigeration requirements.
The pill may be better if:
- You have a phobia of needles or prefer to avoid injections.
- You prefer a daily habit to stay on track with your routine.
- You want a medication that can be stored easily at room temperature.
Check your eligibility for the Wegovy Pill
The MHRA licensed the Wegovy pill for weight management in the UK on 11 June 2026. At PrivateDoc you can pre-order Wegovy Pill now: complete a free online consultation and our UK clinicians will assess whether oral semaglutide is appropriate for you.
Final thoughts
Your doctor or prescriber will help you decide between the Wegovy injection and the Wegovy pill based on your medical history, your lifestyle, and how your body tolerates the medication. Both remain most effective when used alongside a balanced diet, regular physical activity, and ongoing clinical support.
This article is for informational purposes only and does not replace individual medical advice. Availability and approvals of pipeline medications vary by country and are subject to regulatory review by the MHRA. Always consult a qualified healthcare professional before starting or changing any medical treatment.
References
- Knop, F. K., et al. (2023). “Oral semaglutide 50 mg once daily for obesity care (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet.
- Wilding, J. P. H., et al. (2021). “Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1).” New England Journal of Medicine.
- FDA Approvals (2025). “Wegovy (semaglutide) tablets for chronic weight management.”
